Protara Therapeutics Inc. (TARA)
Protara Therapeutics: Carving New Roads In Bladder Cancer
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potentially extending to 3-4 years with a $100 million capital raise. Despite positive early data, the small patient sample size necessitates caution; larger trials are needed to confirm efficacy and safety.
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025.
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
